NRBONeuroBo Pharmaceuticals, Inc.

Nasdaq neurobopharma.com


$ 3.99 $ -0.04 (-0.88 %)    

Friday, 10-May-2024 13:18:07 EDT
QQQ $ 441.71 $ 1.04 (0.24 %)
DIA $ 395.04 $ 1.18 (0.3 %)
SPY $ 520.76 $ 0.67 (0.13 %)
TLT $ 90.14 $ -0.51 (-0.56 %)
GLD $ 218.73 $ 1.76 (0.81 %)
$ 3.96
$ 3.99
$ 0.00 x 0
$ 0.00 x 0
$ 3.99 - $ 3.99
$ 2.89 - $ 6.75
15,915
na
20.15M
$ 1.51
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-28-2024 12-31-2023 10-K
3 11-13-2023 09-30-2023 10-Q
4 08-09-2023 06-30-2023 10-Q
5 05-12-2023 03-31-2023 10-Q
6 03-30-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-12-2022 06-30-2022 10-Q
9 05-13-2022 03-31-2022 10-Q
10 03-31-2022 12-31-2021 10-K
11 11-15-2021 09-30-2021 10-Q
12 08-16-2021 06-30-2021 10-Q
13 05-17-2021 03-31-2021 10-Q
14 04-15-2021 12-31-2020 10-K
15 11-13-2020 09-30-2020 10-Q
16 08-11-2020 06-30-2020 10-Q
17 05-20-2020 03-31-2020 10-Q
18 03-30-2020 12-31-2019 10-K
19 11-08-2019 09-30-2019 10-Q
20 08-09-2019 06-30-2019 10-Q
21 05-09-2019 03-31-2019 10-Q
22 03-18-2019 12-31-2018 10-K
23 11-08-2018 09-30-2018 10-Q
24 08-14-2018 06-30-2018 10-Q
25 05-08-2018 03-31-2018 10-Q
26 03-20-2018 12-31-2017 10-K
27 11-13-2017 09-30-2017 10-Q
28 08-14-2017 06-30-2017 10-Q
29 05-10-2017 03-31-2017 10-Q
30 03-21-2017 12-31-2016 10-K
31 11-02-2016 09-30-2016 10-Q
32 09-14-2016 06-30-2016 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 neurobo-pharmaceuticals-q1-2024-gaap-eps-132-misses-110-estimate

NeuroBo Pharmaceuticals (NASDAQ:NRBO) reported quarterly losses of $(1.32) per share which missed the analyst consensus estimat...

 maxim-group-initiates-coverage-on-neurobo-pharmaceuticals-with-buy-rating-announces-price-target-of-10

Maxim Group analyst Jason McCarthy initiates coverage on NeuroBo Pharmaceuticals (NASDAQ:NRBO) with a Buy rating and announc...

 neurobo-to-present-latest-pre-clinical-data-on-cardiometabolic-assets-da-1241-and-da-1726-targeting-mash-and-obesity-at-scientific-conferences-in-june

NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometa...

 neurobo-pharmaceuticals-files-for-mixed-shelf-offering-of-up-to-150m

https://www.sec.gov/Archives/edgar/data/1638287/000155837024005018/tmb-20240412xs3.htm 

 neurobo-pharmaceuticals-appoints-marshall-h-woodworth-as-chief-financial-officer-effective-march-1-2024

On March 1, 2024, the Board of Directors (the “Board”) of NeuroBo Pharmaceuticals, Inc. (the “Company”) appointed Mr. Marshall ...

 dow-jumps-250-points-honeywell-issues-weak-forecast

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 250 points on Thursday. The Dow t...

 why-ch-robinson-shares-are-trading-lower-by-over-12-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-...

 crude-oil-gains-1-ism-manufacturing-pmi-tops-expectations

U.S. stocks traded higher midway through trading, with the S&P 500 gaining around 0.5% on Thursday. The Dow traded up 0.23...

 why-obesity-drug-maker-neurobo-stock-is-trading-higher

NeuroBo announced that the FDA has cleared its IND application for DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist th...

 nasdaq-surges-100-points-us-jobless-claims-increase-to-224000

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 100 points on Thursday. Following the mark...

Core News & Articles

NRBO: 103% | NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment o...

 neurobo-reports-pre-clinical-safety-data-of-da-1241-in-combination-with-sitagliptin-opens-enrollment-for-part-2-of-phase-2a-clinical-trial-evaluating-da-1241-for-mash-treatment

The pre-clinical results demonstrated that once daily oral administration in rats, of sitagliptin alone (180 mg/kg/day), DA-124...

 neurobo-pharmaceuticals-regains-compliance-with-nasdaq-minimum-price-requirement

NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic dis...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION